Reduced anticoagulation strategy is associated with a lower incidence of intracerebral hemorrhage in COVID-19 patients on extracorporeal membrane oxygenation

Intensive Care Medicine Experimental

Table 2 Thromboembolic complications and type of thromboembolic events during ECMO support according to anti-Xa groups (high vs. low anti-Xa)

	High anti-Xa (n = 93)	Low anti-Xa (n = 48)	Total (n = 141)
Thromboembolic events
Any event overall	12 (12.9%)	6 (12.8%)	18 (12.9%)
Type of thromboembolic event	12 events	6 events	18 events
Pulmonary embolism	5 (41.7%)	1 (16.7%)	6 (33.3%)
DVT	5 (41.7%)	4 (66.7%)	9 (50%)
ECMO lines	1 (8.3%)	0 (0.0%)	1 (5.6%)
Arterial thrombus	1 (8.3%)	0 (0.0%)	1 (5.6%)
Cardiac thrombus	0 (0.0%)	1 (16.7%)	1 (5.6%)

Values are presented as n (%) for categorical data
DVT deep vein thrombosis, ECMO extracorporeal membrane oxygenation
P-value for thromboembolic events overall and for type of thromboembolic event 0.982 and 0.373, respectively (Groups compared by Pearson’s Chi-squared test)